Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DSL101
- Development stage
- Phase 1
- Lead developer
- DSciLab
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Addition/Replacement → Gene Therapies, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
DSL101 is an mRNA-based therapeutic encapsulated in lipid nanoparticles (LNPs) designed for the treatment of Wilson's disease. The therapy consists of mRNA encoding the functional copper-transporting P-type ATPase (ATP7B) protein. Wilson's disease is a rare genetic disorder characterized by mutations in the *ATP7B* gene, which lead to impaired copper excretion from the liver and subsequent toxic accumulation in various tissues, particularly the liver and brain. By delivering the functional mRNA directly to hepatocytes via LNPs, DSL101 aims to restore the liver's ability to transport and excrete copper, thereby mitigating the systemic toxicity associated with the disease. Developed by DSciLab Co., Ltd., DSL101 is currently undergoing early-phase clinical evaluation to assess its safety, tolerability, and preliminary efficacy as a potential gene therapy-like intervention that bypasses the need for permanent genomic modification.
- Other names
- ATP7B mRNA/LNPDSL-101DSL101DSL 101
02
Targets
ATP7B (Copper ion transporter ATPase 7B)
Beyond the preview
Go deeper on DSL101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DSL101.